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TrachelectomyWe report the ﬁrst case of an unequivocal ovarian recurrence from
a FIGO stage 1b1 cervical adenocarcinoma following previous treat-
ment by radical vaginal trachelectomy and laparoscopic bilateral pel-
vic lymphadenectomy (RVT & LPLND).
A 32 years oldwoman, para one, was referred to the unit for a second
opinion regarding treatment options for a cervical cancer. She initially
presented following an abnormal smear (high grade Cervical Glandular
Intraepithelial Neoplasia—CGIN) and new onset post-coital bleeding.
Her last smear, 7 years previously, was normal. She had no signiﬁcant
past medical or surgical history.
Colposcopy at presentation revealed an ulcerated lesion on the an-
terior lip of the cervix measuring 1 cm×1.5 cm. This was conﬁrmed
to be a grade II mucinous adenocarcinoma on a background of CGIN
without vascular invasion. MRI revealed no detectable cervical or
parametrial disease nor any pelvic lymphadenopathy. On the basis
of these ﬁndings, an initial diagnosis of FIGO stage 1b1 disease was
made. After careful counselling, in accordance with her wishes for
fertility-sparing surgery, she was scheduled for RVT & LPLND, which
was carried out, with no complication, as previously described
(Shepherd and Milliken, 2008).
Final histology conﬁrmed a Stage 1b1 G2 adenocarcinoma with a
maximal horizontal diameter of 15 mm and a depth of 3.4 mm,
12 mm from the vaginal resection margin with no parametrial inva-
sion. There was no evidence of lymphovascular space invasion. All⁎ Corresponding author. Fax: +44 207 8118104.
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not indicated.
The woman was followed up in accordance with our Centre guide-
lines with clinic visits, imaging and multidisciplinary team (MDM) re-
view (Shepherd and Milliken, 2008). The ﬁrst two years of follow-up
were uneventful.
At 24 months, her routine MRI showed a right ovarian cyst mea-
suring 11 cm×10 cm, containing a few ﬁne septations but no solid
component. Physical examination of the woman soon after the MRI
revealed a mobile 10 cm pelvic mass palpable per vagina, with no as-
sociated lymphadenopathy. All blood tests, including tumour markers
were normal; CA125 b15 IU/mL, CEA b2mcg/L, CA19-9 3.9kunits/L.
Tumour markers had not been tested at presentation. At MDM review
it was conﬁrmed that the radiological impression was that the lesion
was most likely benign, but in view of its de novo nature and size sur-
gical removal was advised. Although the patient was asymptomatic,
she agreed to laparoscopy for ovarian cystectomy.
Unfortunately, due to unforeseen circumstances, her operation was
cancelled, rescheduled and cancelled again at short notice. In view of
the delay between the MDM decision and the likely procedure date, a
repeat pelvic MRI was obtained at 28 months post RVT. This revealed
an enlarging mass, now measuring 18.7 cm×17.4 cm×16.6 cm, dem-
onstrating increased complexity but remaining unsuggestive of malig-
nancy. The right ovary, uterus, trachelectomy anastomosis, bladder
and rectum all appeared normal. CA125 remained normal, b15 IU/mL.
Regrettably, the increase in cyst size meant that a laparoscopic proce-
dure was no longer considered appropriate, and she was listed for
laparotomy. She underwent an uncomplicated midline laparotomy
and left salpingo-oophorectomy at which a 20 cm benign looking left
ovarian cystwas removed. No normal left ovarian tissuewas identiﬁable.
The right ovary, bowel, omentum, diaphragm and liver were normal.
Macroscopically this was a cyst with a smooth outer surface. Inter-
nally the cyst was multiloculated with a few velvety areas on the
inner surface but no solid or papillary foci. Histology showed cystic
and glandular spaces lined by uniformly atypical mucinous epithelium.
The lining cells were tall and columnar with numerous interspersed
goblet cells. A single mural nodule of invasive carcinoma with chon-
droid stroma was present. Immunohistochemistry and HPV testing
was used to ascertain the nature of this neoplasam; on immunohisto-
chemistry tumour cells were diffusely and strongly positive for p16,
together with positive staining for cytokeratin 7 and carcinoembryonic
antigen. Staining for cytokeratin 20 was negative. HPV testing carried
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DNA. The fallopian tube was normal. On the basis of these ﬁndings the
diagnosis of isolated ovarian metastasis from the previous cervical
adenocarcinoma was made.
She subsequently had a negative whole body FGD-PET scan. She
had a course of ovarian stimulation and egg retrieval prior to com-
mencing pelvic radiotherapy and concomitant chemotherapy; 50.4
Gray in 28 fractions via 15 MV photon ﬁelds to the 100% isodose.
She received ﬁve cycles of concurrent cisplatin with no signiﬁcant
toxicities. Following this she received three cycles of carboplatin
and paclitaxel. Due to malaise and parasthesia the woman opted not
to receive the planned ﬁnal fourth cycle of adjuvant chemotherapy.
Post treatment imaging showed no evidence of local or regional recur-
rence. At most recent follow-up, 8 months after completion of chemor-
adiotherapy, she was well with no symptoms or signs on examination
suggestive of further recurrence.
Discussion
First described by Dargent in 1994 and subsequently reﬁned by
Shepherd et al., RVT has emerged as a fertility-sparing operation suit-
able for selected patients with stage I cervical cancer. A recent article
reviewing 790 radical vaginal trachelectomy cases showed that 302
pregnancies have yielded190 live births (Shepherd andMilliken, 2008).
A review of the published literature suggests that out of 829 cases
reported as part of trachelectomy case series, there have been 27 re-
currences (3.25%) resulting in 15 deaths (1.8% of all cases, 55.5% of all
recurrences). The mean reported time to recurrence is 30.6 months
(range 3 to 93 months). Time to recurrence data are reported for 26
of the 27 recurrences (see Table 1). This compares favourably with
reported survival rates for IB1 cervical cancer treated with radical
hysterectomy; Benedet et al. report a 5-year survival of 80.7% in the
2470 women with stage 1b1 carcinoma of the cervix treated from
1993 to 1995 (Benedet et al., 2001).
Ovarian metastasis of cervical cancer has been well documented
within the literature. The effect of histological cervical type is however
uncertain. Sutton et al. in their study of 990 patients with stage Ib cervi-
cal cancer report an ovarian recurrence rate of 1.7% for adenocarcinoma
and 0.5% for squamous cell carcinoma; this difference is statistically
non-signiﬁcant (Sutton et al., 1992). Conversely, a post mortem studyTable 1
Radical trachelectomy outcomes, literature review.
Reference Number % AC Recurrence Deaths Me
(m
Milliken and Shepherd 158 n/a 4 4 45
Beiner et al. 137 49 5 3 51
Marchiole et al. 118 21 7 5 95
Plante et al. 125 37 6 2 93
Hertel et al. 100 31 4 2 29
Roman et al. 69 - 2 0 31
Jin Li et al. 64 13 0 0 23
Sonoda et al. 43 37 1 0 21
Querlou 29 n/a 1 0 n/a
Svane 24 n/a 0 0 n/a
Maneo et al. 21 57 0 0 69
Chen et al. 16 n/a 0 0 28
Hellberg 8 n/a 0 0 n/a
Total 893 Av 35% 30 (3.4%) 16 (1.8%) Av
AC=Adenocarcinoma.
n/a=Not available.
F/U=Follow up.reporting on 674 autopsy specimens put the overall ovarian metastasis
rate from advanced adenocarcinoma and squamous cell carcinoma of
the cervix at 28.6% and 17.4% respectively, pb0.02 (Tabata et al.,
1987). Also Shimada et al. demonstrated a statistically signiﬁcant differ-
ence between the two in their large radical hysterectomy series, with
an ovarian metastasis rate from Ib cervical cancers of 3.72% for adeno-
carcinoma but only 0.22% for squamous cell primaries (Shimada et al.,
2006).
Several factors are recognised to be important when calculating
the risk of recurrence from early cervical cancer. These include the
diameter of the tumour, depth of invasion, tumour grade, tumour stage
and evidence of nodal involvement. Following RVT our patient had no
recognised adverse prognostic factors.
In 2005, Piketty et al. published what is held to be the ﬁrst ovarian
recurrence of a microinvasive cervical adenocarcinoma treated by RVT
(Piketty et al., 2005). Metastasis from the previous cervical adenocarci-
nomawas suggested on the basis of the ovarian tumour immunochem-
istry; CK7 positive and CK 20 negative tumour cells. While this may
indeed represent an ovarian recurrence, their reported histopathology
cannot exclude this being a metastatic upper gastrointestinal tract ade-
nocarcinoma. In their paper looking at immunohistochemisty of primary
and secondary mucinous ovarian neoplasms, Vang et al. demonstrated
that a CK7+/CK20− proﬁle was observed in primary ovarian tumours
(74%), as well as metastases from upper gastrointestinal tract (78%),
and endocervical adenocarcinomas (88%) (Vang et al., 2006).
In their recent case series of 29 endocervical adenocarcinomas
with ovarian metastases, Ronnett et al. demonstrated that in all
cases of HPV-related cervical cancer studied, the paired ovarianmetas-
tasis contained identical HPV subtypes. These HPV-related tumours
also strongly expressed p16/INK, while non-HPV related tumours did
not (Ronnett et al., 2008). The immunohistochemistry proﬁle of our
patient's ovarian tumour and the identiﬁcation ofHPV 18 in the ovarian
neoplasm indicate without a doubt that her ovarian tumour originated
from the preceding cervical adenocarcinoma.
Our case also shares the unusual features seen in this pattern of
ovarian metastasis highlighted in the series of Ronnett et al. (2008).
While metastatic mucinous ovarian carcinomas are typically bilateral
and inﬁltrative, involvement of the ovaries from invasive endocervi-
cal adenocarcinomas typically occurs as unilateral cystic masses
with a lack of macroscopic, and therefore radiological, featuresan F/U
onths)
Sites (time to recurrence, where given)
Paraaortic region (90/12); left pelvic side wall (51/12);
left paracervical tissue (26/12); vaginal vault (7/12)
Para-aortic and supra-clavicular regions (70/12); pelvic wall (54/12);
-aortic region (44/12); upper abdomen (15/12); lung (10/12)
Lateropelvic (93/12); lateropelvic and lung (21/12); liver, lung,
lumbo-aortic nodes (20/12); bilateral suparenal glands and lombo-aortic
nodes (19/12); parametrial and lumbo-aortic nodes (18/12); lumbo-aortic
nodes (11/12); parametrial (and lung (7/12)
Parametrium (72/12), parametrium (9/12), parametrium (18/12),
residual cervix (36/12), mesocolon (15/12), widely metastatic (‘rapid’)
Cervix (34/12); pelvic side wall (11/12); uterus (7/12); corpus (3/12)
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mary ovarian borderline tumours. Such metastases are reported to
present prior to, concurrently with or up to 7 years after the endocer-
vical neoplasm. In the Ronnett series, 17 of 19 patients who under-
went lymphadenectomy had no lymph nodal metastasis, and of the
18 cases with available follow-up, 14 patients were alive with no ev-
idence of disease (10–83 months' follow-up period) and two others
were alive with disease. Due to these unusual pathological features
and apparently favourable clinical outcome, the possibility that this
represents an example of an independent ovarian neoplasm as a
result of a ‘ﬁeld effect’ of oncogenic HPV has also been suggested
(Reichert, 2005a) though refuted (Reichert, 2005b).
This case identiﬁes the importance of follow up for women previously
treated for an early cervical cancer. We recognise that imaging will never
have 100% sensitivity for detecting malignant disease and that the most
effective imaging modality for use in follow up is unclear. Additionally,
this case highlights the view that any new pelvic abnormality must
be managed in light of the possibility that it is a recurrence of previously
appropriately treated cervical cancer.
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